Use the hyperlinks, where available to access additional clinical trial information.
Phase II Study of Intravenous Vinorelbine in Patients With Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer
Other Non-Commercial Sponsor
National University Hospital, Singapore
The purpose of this trial is to determine if targeting platinum resistant or refractory C5 high-grade serous, high grade endometrioid or undifferentiated ovarian, primary peritoneal and Fallopian tube with vinorelbine can improve patient outcomes.
Patients will receive Vinorelbine 25 mg/m2 intravenously on day-1 and day-8 of a 3 week cycle. Drug administration will commence following confirmation of eligibility into the study for a maximum of 12 months, until disease progression, intolerable toxicity or withdrawal of patient consent (whichever event occurs first).